ABC & SCAI: Advancing Health Equity in Secondary ASCVD and Lp(a) Management-Lp(a)? Probably Not So Little! Insights and Management Strategies, Dr. Karol Watson

Lp(a)? Probably Not So Little! Insights and Management Strategies, Dr. Karol Watson

Video Transcription

Video Summary

The discussion focuses on lipoprotein(a) or LP(a), which is similar to LDL cholesterol but attached to an apolipoprotein(a) with Kringle type 4 repeats. LP(a) is a significant cardiac risk factor, increasing the risk of atherosclerosis, thrombosis, and inflammation due to its structure. Although LP(a) levels are genetically determined and cannot be easily altered by lifestyle changes or current medications, new therapies—like antisense oligonucleotides—are in development to specifically lower LP(a) levels. There's evidence suggesting that high LP(a) levels are a more critical concern for African Americans. Screening is recommended for high-risk individuals.

Keywords

Lipoprotein(a)

Cardiac risk factor

Antisense oligonucleotides

Atherosclerosis

Screening